BioMed Research International / 2021 / Article / Tab 3 / Research Article
Role of Aminoglycoside-Modifying Enzymes (AMEs) in Resistance to Aminoglycosides among Clinical Isolates of Pseudomonas aeruginosa in the North of Iran Table 3 The correlation between the AME gene profile of P. aeruginosa clinical isolates and the MIC ranges of aminoglycosides.
Genotypes No. (%) of MDRs No. (%) of isolates with different MICs (μ g/ml) against amikacin No. (%) of isolates with different MICs (μ g/ml) against gentamicin No. (%) of isolates with different MICs (μ g/ml) against tobramycin No. (%) of isolates with different MICs (μ g/ml) against netilmicin ≤16 32 64-128 ≥256 ≤4 8 16-128 ≥256 ≤4 8 16-128 ≥256 ≤8 16 32-128 ≥256 ANT(3 )-Ia (7 (87.5) 5 (62.5) 1 (12.5) 0 2 (25) 1 (12.5) 0 2 (25) 5 (62.5) 1 (12.5) 0 6 (75) 1 (12.5) 1 (12.5) 0 (0) 7 (87.5) 0 ANT(2 )-Ia (5 (83.3) 2 (33.3) 2 (33.3) 2 (33.3) 0 0 0 2 (33.3) 4 (66.6) 0 0 4 (66.6) 2 (33.3) 1 (16.6) 1 (16.6) 3 (50) 1 (16.6) AAC(6 )-Ib (24 (92.3) 11 (42.3) 4 (15.3) 7 (26.9) 4 (15.3) 1 (3.8) 1 (3.8) 3 (11.5) 21 (80.7) 1 (3.8) 0 12 (46.1) 13 (50) 3 (11.5) 0 18 (69.2) 5 (19.2) AAC(6 )-IIa (16 (88.8) 10 (55.5) 3 (16.6) 3 (16.6) 2 (11.1) 2 (11.1) 1 (5.5) 4 (22.2) 11 (61.1) 2 (11.1) 0 10 (55.5) 6 (33.3) 4 (22.2) 0 12 (66.6) 2 (11.1) APH(3 )-IIb (13 (86.6) 7 (46.6) 3 (20) 3 (20) 2 (13.3) 1 (6.6) 0 4 (26.6) 10 (66.6) 1 (6.6) 0 9 (60) 5 (33.3) 2 (13.3) 1 (6.6) 10 (66.6) 2 (13.3) APH(3 )-Ib (0 1 (100) 0 0 0 0 0 1 (100) 0 0 0 1 (100) 0 0 1 (100) 0 0 ANT(3 )-Ia+ ANT(2 )Ia (2 (100) 1 (50) 1 (50) 0 0 0 0 1 (50) 1 (50) 0 0 1 (50) 1 (50) 1 (50) 0 1 (50) 0 ANT(3 )-Ia+ AAC(6 )-Ib (5 (83.3) 4 (66.6) 1 (16.6) 0 1 (16.6) 0 0 2 (33.3) 4 (66.6) 0 0 5 (83.3) 1 (16.6) 1 (16.6) 0 5 (83.3) 0 ANT(3 )-Ia+ AAC(6 )-IIa (2 (66.6) 2 (66.6) 1 (33.3) 0 0 0 0 1 (33.3) 2 (66.6) 0 0 2 (66.6) 1 (33.3) 1 (33.3) 0 2 (66.6) 0 ANT(3 )-Ia+ APH(3 )-IIb (3 (75) 2 (50) 1 (25) 0 1 (25) 0 0 1 (25) 3 (75) 0 0 3 (75) 1 (25) 1 (25) 0 3 (75) 0 ANT(2 )-Ia+ AAC(6 )-Ib (5 (100) 1 (20) 2 (40) 2 (40) 0 0 0 1 (20) 4 (80) 0 0 2 (40) 3 (60) 1 (20) 0 3 (60) 1 (20) ANT(2 )-Ia+ AAC(6 )-IIa (5 (100) 1 (20) 2 (40) 2 (40) 0 0 0 1 (20) 4 (80) 0 0 2 (40) 3 (60) 1 (20) 0 3 (60) 1 (20) ANT(2 )-Ia+ APH(3 )-IIb (5 (83.3) 2 (33.3) 2 (33.3) 2 (33.3) 0 0 0 2 (33.3) 4 (66.6) 0 0 3 (50) 3 (50) 1 (16.6) 1 (16.6) 3 (50) 1 (16.6) ANT(2 )-Ia+ APH(3 )-Ib (0 1 (100) 0 0 0 0 0 1 (100) 0 0 0 1 (100) 0 0 1 (100) 0 0 AAC(6 )-Ib+ AAC(6 )-IIa (12 (85.7) 7 (50) 2 (14.2) 3 (21.4) 2 (14.2) 0 1 (7.1) 2 (14.2) 11 (78.5) 0 0 8 (57.1) 6 (42.8) 3 (21.4) 0 9 (64.2) 2 (14.2) AAC(6 )-Ib+ APH(3 )-IIb (8 (88.8) 3 (33.3) 2 (22.2) 3 (33.3) 1 (11.1) 0 0 1 (11.1) 8 (88.8) 0 0 5 (55.5) 4 (44.4) 1 (11.1) 0 6 (66.6) 2 (22.2) AAC(6 )-IIa+ APH(3 )-IIb (11 (91.66) 5 (41.6) 3 (25) 3 (25) 1 (8.3) 1 (8.3) 0 3 (25) 8 (66.6) 1 (8.3) 0 7 (58.3) 4 (33.3) 2 (16.6) 0 8 (66.6) 2 (16.6) APH(3 )-IIb+ APH(3 )-Ib (0 1 (100) 0 0 0 0 0 1 (100) 0 0 0 1 (100) 0 0 1 (100) 0 0 ANT(3 )-Ia + ANT(2 )-Ia+ AAC(6 )-Ib (2 (100) 1 (50) 1 (50) 0 0 0 0 1 (50) 1 (50) 0 0 1 (50) 1 (50) 1 (50) 0 1 (50) 0 ANT(3 )-Ia + ANT(2 )-Ia+ AAC(6 )-IIa (2 (100) 1 (50) 1 (50) 0 0 0 0 1 (50) 1 (50) 0 0 1 (50) 1 (50) 1 (50) 0 1 (50) 0 ANT(3 )-Ia + ANT(2 )-Ia+ APH(3)-IIb (2 (100) 1 (50) 1 (50) 0 0 0 0 1 (50) 1 (50) 0 0 1 (50) 1 (50) 1 (50) 0 1 (50) 0 ANT(3 )-Ia+ APH(3)-IIb+ AAC(6 )-Ib (2 (66.6) 2 (66.6) 1 (33.3) 0 0 0 0 1 (33.3) 2 (66.6) 0 0 0 0 1 (33.3) 0 2 (66.6) 0 ANT(3 )-Ia+ APH(3 )-IIb+ AAC(6 )-IIa (2 (66.6) 2 (66.6) 1 (33.3) 0 0 0 0 1 (33.3) 2 (66.6) 0 0 2 (66.6) 1 (33.3) 1 (33.3) 0 2 (66.6) 0 ANT(3 )-Ia+ AAC(6 )-Ib+ AAC(6 )-IIa (2 (66.6) 2 (66.6) 1 (33.3) 0 0 0 0 1 (33.3) 2 (66.6) 0 0 2 (66.6) 1 (33.3) 1 (33.3) 0 2 (66.6) 0 ANT(2 )-Ia+ APH(3 )-IIb+ AAC(6 )-Ib (5 (100) 1 (20) 2 (40) 2 (40) 0 0 0 1 (20) 4 (80) 0 0 3 (60) 2 (40) 1 (20) 0 3 (60) 1 (20) ANT(2 )-Ia+ AAC(6 )-Ib+ AAC(6 )-IIa (5 (100) 1 (20) 2 (40) 2 (40) 0 0 0 1 (20) 4 (80) 0 0 3 (60) 2 (40) 1 (20) 0 3 (60) 1 (20) APH(3 )-IIb+ AAC(6 )-Ib+ AAC(6 )-IIa (8 (88.8) 3 (33.3) 2 (22.2) 3 (33.3) 1 (11.1) 0 0 1 (11.1) 8 (88.8) 0 0 5 (55.5) 4 (44.4) 1 (11.1) 0 6 (66.6) 2 (22.2) ANT(2 )-Ia+ APH(3 )-IIb+ APH(3 )-Ib (0 1 (100) 0 0 0 0 0 1 (100) 0 0 0 1 (100) 0 0 1 (100) 0 0 ANT(3 )-Ia+ ANT(2 )-Ia+ APH(3 )-IIb+ AAC(6 )-Ib (2 (100) 1 (50) 1 (50) 0 0 0 0 1 (50) 1 (50) 0 0 1 (50) 1 (50) 1 (50) 0 1 (50) 0 ANT(2 )-Ia+ APH(3 )-IIb+ AAC(6 )-Ib+ AAC(6 )-IIa (5 (100) 1 (20) 2 (40) 2 (40) 0 0 0 1 (20) 4 (80) 0 0 3 (60) 2 (40) 1 (20) 0 3 (60) 1 (20) ANT(3 )-Ia+ APH(3 )-IIb+ AAC(6 )-Ib+ AAC(6 )-IIa (2 (66.6) 2 (66.6) 1 (33.3) 0 0 0 0 1 (33.3) 2 (66.6) 0 0 2 (66.6) 1 (33.3) 1 (33.3) 0 2 (66.6) 0 ANT(3 )-Ia+ ANT(2 )-Ia+ AAC(6 )-Ib+ AAC(6 )-IIa (2 (100) 1 (50) 1 (50) 0 0 0 0 1 (50) 1 (50) 0 0 1 (50) 1 (50) 1 (50) 0 1 (50) 0 ANT(3 )-Ia+ ANT(2 )-Ia+ APH(3 )-IIb+ AAC(6 )-IIa (2 (100) 1 (50) 1 (50) 0 0 0 0 1 (50) 1 (50) 0 0 1 (50) 1 (50) 1 (50) 0 1 (50) 0 ANT(3 )-Ia+ ANT(2 )-Ia+ APH(3 )-IIb+ AAC(6 )-Ib+ AAC(6 )-IIa (2 (100) 1 (50) 1 (50) 0 0 0 0 1 (50) 1 (50) 0 0 1 (50) 1 (50) 1 (50) 0 1 (50) 0
